Access to toxicity study reports and protection of commercial interests
Written By
Senior Associate
Belgium
I am a senior associate in the Regulatory, Public & Administrative Law department in our Brussels office. I advise both Belgian and international clients on regulatory matters across several sectors, especially in the Life Sciences and the Energy sectors.
Gerard Hogan, Advocate General at the Court of Justice of the European Union (“CJEU”) recently delivered an opinion in the pending case between MSD Animal Health Innovation (“MSD”), Intervet international (“Intervet”) and the European Medicines Agency (“EMA”). In his opinion, due to their commercial value toxicity study reports are covered by a general presumption of confidentiality and their disclosure may only be granted under very strict conditions.
Accordingly, Advocate General Hogan recommends the annulment of the General Court’s previous judgment, which ruled in favour of the widest possible access to such reports. Although the Advocate General’s opinions are not binding this position illustrates the ongoing contest before the CJEU on one of the major topics for the life-science industry.
Latest insights
More Insights
Mitigating the legal risks of licencing in open-source software and database elements
7 minutes Jun 17 2025
SG Trade Marks Fast Programme: Accelerated Examination for Local Applications in Singapore
Jun 12 2025
What the UK-US ‘trade deal’ means for businesses on both sides of the Atlantic
7 minutes Jun 03 2025